Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06332534 · ClinicalTrials.gov registry record · Phase 3
Crohn's Disease: Efficacy, Safety, and Pharmacokinetics of Upadacitinib in Pediatric Subjects With Moderately to Severely Active Crohn's Disease
A Phase 3 study of Crohn's Disease, sponsored by AbbVie.
- Recruiting
- Registry status
- Phase 3
- Development phase
- 110
- Enrollment target
- 20
- Study locations
NCT06332534 is a Phase 3 study of Crohn's Disease that is actively recruiting participants, run by AbbVie. The registered enrollment target is 110 participants, below the 2,414-participant average among 104 other Crohn's Disease trials with a reported enrollment target (95% lower). The trial reports 20 study locations across 18 states.
The verdict
NCT06332534, a Phase 3 study of Crohn's Disease, is actively recruiting participants, sponsored by AbbVie.
- RECRUITING
- Registry status
- Phase 3
- Development phase
- 110 participants
- Enrollment target
- 20
- Study locations
Study Summary
Crohn's disease (CD) is a long-lasting disease that causes severe inflammation (redness, swelling), in the digestive tract, most often affecting the bowels. It can cause many different symptoms including abdominal pain, diarrhea, tiredness, and weight loss. This study will assess how safe and effective oral Upadacitinib is in treating moderately to severely active Crohn's Disease in pediatric participants aged 2 to 18 years old who have had inadequate response, loss of response, intolerance, or medical contraindications to corticosteroids, immunosuppressants, and/or biologic therapy. Upadacitinib (RINVOQ) is a drug approved in adults for moderate- to severely active CD and is being developed for moderate- to severely active CD in pediatric participants. This study is conducted in 2 periods: Period 1 is comprised of two phases: a 12-week open-label induction phase which means that the study doctor and participants know that participants will receive UPA Dose-A (or the adult equivalent based on body weight) followed by a 52-week double-blind maintenance phase meaning that neither the participants nor the study doctors will know which dose of upadacitinib will be given(UPA Dose B or Dose C). Period 2 is a 156-week open-label extension of Period 1. Approximately 110 pediatric participants with moderate to severely active CD will be enrolled at approximately 92 sites worldwide. Participants will receive upadacitinib oral tablets once daily or oral solution twice daily at approximately the same time each day, with or without food. Participants will have a safety follow up for 30 days after discontinuation from any time point within the study. There may be higher treatment burden for participants in this trial compared to their standard of care (due to study procedures). Participants will attend regular (weekly, monthly) visits during the study at a hospital or clinic. The effect of the treatment will be checked by medical assessments, blood tests, checking for side eff
Conditions Studied
Interventions
- DRUG Upadacitinib
Study Locations (20)
California
- UCSF Benioff Children's Hospital - Oakland /ID# 262217 - Oakland
- Lucile Packard Children's Hospital /ID# 262193 - Palo Alto
New South Wales
- Sydney Children's Hospital /ID# 262352 - Randwick
- Children's Hospital at Westmead /ID# 262350 - Westmead
Colorado
- Children's Hospital Colorado - Aurora /ID# 262207 - Aurora
Connecticut
- Connecticut Children's Medical Center - Hartford /ID# 262256 - Hartford
Illinois
- OSF St. Francis Medical Center /ID# 262192 - Peoria
Indiana
- Indiana University Health Riley Hospital for Children /ID# 262215 - Indianapolis
Massachusetts
- Boston Children's Hospital /ID# 262191 - Boston
Minnesota
- MNGI Digestive Health, P. A. /ID# 262204 - Minneapolis
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 110 participants |
| Start Date | 2024-07-26 |
| Est. Completion | 2034-12 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06332534
The ClinicalTrials.gov registry entry for NCT06332534 describes a study currently listed as recruiting, categorized as Phase 3. The registered enrollment target is 110 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 2,414-participant average among 104 other Crohn's Disease trials with a reported enrollment target (95% lower). The listed sponsor is AbbVie, which has 526 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Crohn's Disease appearing as the primary indexed condition, and to 1 intervention - of which Upadacitinib is the first listed.
NCT06332534 reports 20 study locations spanning 18 distinct geographic areas - top geographies include California, New South Wales, Colorado.
Frequently Asked Questions
What is clinical trial NCT06332534 about?
NCT06332534 is a clinical study titled "Crohn's Disease: Efficacy, Safety, and Pharmacokinetics of Upadacitinib in Pediatric Subjects With Moderately to Severely Active Crohn's Disease". Crohn's disease (CD) is a long-lasting disease that causes severe inflammation (redness, swelling), in the digestive tract, most often affecting the bowels. It can cause many different symptoms including abdominal pain, diarrhea, tiredness, and weight loss. This study will assess how safe and effect...
What is the current status of trial NCT06332534?
This trial is currently recruiting. It is a Phase 3 study. The enrollment target is 110 participants. The study started on 2024-07-26. Estimated completion is 2034-12.
What conditions does trial NCT06332534 study?
This clinical trial studies the following conditions: Crohn's Disease.
What interventions are being tested in trial NCT06332534?
The interventions under investigation include: Upadacitinib (DRUG).
Who is sponsoring clinical trial NCT06332534?
This trial is sponsored by AbbVie, which has 526 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06332534 being conducted?
This trial has 20 study locations across California, Colorado, Connecticut, Illinois, Indiana. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Crohn's Disease
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Testing the Role of Anti-fungal Therapy in Improving the Response to Therapies for Crohn's Disease
RECRUITING · Phase 3
-
Transmural Healing and Disease-Modifying Effect of Guselkumab in Crohn's Disease Patients
RECRUITING · Phase 3
-
A Study of Mirikizumab (LY3074828) in Pediatric Participants With Crohn's Disease
RECRUITING · Phase 3
-
An Induction Study to Investigate the Efficacy and Safety of Duvakitug in Participants With Moderately to Severely Active Crohn's Disease
RECRUITING · Phase 3
-
A Study of Vedolizumab With and Without Upadacitinib in Adults With Crohn's Disease
RECRUITING · Phase 3
-
A Study of Guselkumab in Pediatric Participants With Moderately to Severely Active Crohn's Disease
RECRUITING · Phase 3
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.